An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

(MENAFN- EIN Presswire) Crohn's disease companies working in the market are Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma, and more. LAS VEGAS ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Janssen’s Stelara has gained FDA approval for use in patients with Crohn’s disease who have failed treatment or were intolerant to a TNF blocker drug. The monoclonal antibody drug targets ...

linking the pathogenesis of Crohn’s disease with this inflammation pathway. The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

Crohn's disease and ulcerative colitis look set to ... with results of a head-to-head trial pitting the antibody against Stelara due later this year. "With more than 30 ongoing or planned trials ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the ... alongside the IL-12/23 blockbuster Stelara (ustekinumab, Janssen) and a logjam ...

In Crohn's disease patients, adherence to a Mediterranean ... (Gastroenterology) Combing 5-aminosalicylic acid with ustekinumab (Stelara) did not appear to provide a clinical benefit in IBD ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million ...